Maria Dragun

Ms. Dragun’s representative experience includes advising:

• SynAffix and its selling shareholders on its sale to Lonza. Under the terms of the sale and purchase agreement, Lonza have paid Synaffix’s shareholders an upfront payment of €100 million, with the potential for shareholders to receive an additional payment of up to €60 million contingent on financial performance
• Immunocore Limited, a leading clinical-stage T cell receptor biotechnology company, on its collaboration with the Bill & Melinda Gates Foundation, including an investment of up to $40 million to support development of certain immunotherapies for infectious diseases*
• Immunocore Limited on its $130 million Series B funding round led by General Atlantic*
• A leading British life sciences company on a number of equity financings, comprising both placings for existing shareholders and funding from new investors of up to c. $100 million, as well as general corporate advisory matters*
• A leading VC fund on its Series A investment in a mental health technology company*
• Aquis Exchange plc, the pan-European equities exchange operator and technology service provider, on its initial public offering on AIM*
• A leading British life sciences company on its initial public offering on the Main Market of the LSE*

*Denotes experience prior to joining Goodwin.